

**TITLE: PCSK9 acts as a key regulator of A β clearance across the
blood-brain barrier**

Cellular and Molecular Life Sciences

AUTHORS: Alexander D. Mazura¹ (0000-0002-2899-6183), Anke Ohler¹, Steffen E. Storck¹
(0000-0002-6965-2264), Magdalena Kurtyka¹, Franka Scharfenberg², Sascha Weggen³,
Christoph Becker-Pauly², Claus U. Pietrzik¹


AFFILIATIONS

¹Institute of Pathobiochemistry, University Medical Center of the Johannes Gutenberg-
University Mainz; Mainz, 55128, Germany.

²Institute of Biochemistry, Christian Albrecht University of Kiel; Kiel, 24098, Germany.

³Department of Neuropathology, Heinrich Heine University Düsseldorf; Düsseldorf, 40225,
Germany.

Corresponding author: Claus U. Pietrzik, Institute of Pathobiochemistry, University Medical
Center of the Johannes Gutenberg-University Mainz; Duesbergweg 6., 55128
Mainz, Germany; Phone: +49 6131 39 25390; Email: pietrzik@uni-mainz.de



Supplementary Fig. 1 No substantial differences in BBB integrity *in vitro*. Luminal

[^{14}C]-radioactivity after conducting the *in vitro* transport studies displayed in (A) Fig. 1A and (B - D) 2A + B were normalized to control mean (first column of graph section) and depicted as percentage of inulin diffusion. Data represents mean $\pm$ SEM of (A) $n = 6 - 12$, (B + C) $n = 8 - 13$, or (D) $n = 9 - 10$ per group of at least two independent experiments. For statistical analyses unpaired two-tailed t -test was used ($*p < 0.05$)